16 september 2016: Het volledige studierapport van onderstaande studie is in te zien via deze PDF: 

http://www.j-smu.com/pdf2/200710/2007101501.pdf welke gedeeltelijk in het Engels is en gedeeltelijk in het Chinees.

Interessant is ook deze studie: Postoperative intraperitioneal hyperthermic chemoperfusion combined with intravenous chemotherapy for 82 advanced gastric cancer patients waarvan het volledige studierapport ook in het Chinees is. 

16 februari 2008: Bron: 1:  Nan Fang Yi Ke Da Xue Xue Bao. 2007 Oct;27(10):1501-3.Click here to read

Hyperthermie met endogenic field naast FOLFOX chemo regiem verbetert significant overlevingstijd van patienten met gevorderde darmkanker stadium II - IV. Aldus een gerandomiseerde langjarige studie bij 136 patienten

RESULTATEN: De response was 68.4% in de behandelingsgroep en 36.4% in de controle groep, dit is een significant verschil (P<0.05). De 1-jaars overleving was 88.2% in de behandelingsgroep, nagenoeg gelijk aan de 81.0% in de controle groep (P< 0.05), maar de 3 en 5-jaars overleving in de behandelingsgroep (67.6% en 30.9%) was significant hoger dan die in de controle groep (47.6% en 15.4%, P<0.05). De bijwerkingen waren gelijk tussen beide groepen.

[Postoperative abdominal endogenic field hyperthermia combined with FOLFOX regimen in the treatment of 68 cases of advanced gastric cancer]

[Article in Chinese]

 

Department of Oncology, Second Affiliated Hospital of Sun Yat-sen University, Guangzhou 510120, China. lxg1005@126.com

OBJECTIVE: To assess the therapeutic efficacy and adverse effects of endogenetic field hyperthermia (EFH) in combination with L-OHP /LV / 5-FU in the treatment of advanced gastric cancer.

METHODS: This study included 147 surgical patients with stage II-IV gastric cancer, who received postoperative chemotherapy with FOLFOX (L-OHP 85 mg /m square, 3 h intravenous infusion, followed by infusion of LV at 200 mg /m square in 2 h, intravenous injection of 5-Fu at 400 mg /m square, and intravenous infusion of 5-FU at 3000 mg /m square in 48 h). Eight treatment cycles (each lasting for 14 days) were administered. In 68 cases randomly selected from the cohort, EFH was performed on the first and third days (treatment group), but not in the other 79 cases (control group).

RESULTS: The response rate was 68.4% in the treatment group and 36.4% in the control group, showing significant difference between them (P<0.05). The 1-year survival rate was 88.2% in the treatment group, similar to the rate of 81.0% in the control group (P< 0.05), but the 3, 5-year survival rates in treatment group (67.6% and 30.9%) was significantly higher than those in the control group (47.6% and 15.4%, P<0.05). The adverse effects were similar between the two groups.

CONCLUSION: EFH combined with the chemotherapeutic regimen FOLFOX might improve the therapeutic effect of stage II-IV gastric cancer without obviously increasing the adverse effects.

PMID: 17959524 [PubMed - in process]


Plaats een reactie ...

Reageer op "Darmkanker: Hyperthermie naast FOLFOX chemo regiem bij gevorderde darmkanker (stadium II tot IV) verdubbelt 5 jaars overleving t.o.v. controlegroep (30 procent t.o. 15 procent"


Gerelateerde artikelen